118811-07-7

Basic information

• Product Name: 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: N-BOC-4-TOXYLOXY-PIPERIDINE;4-(Toluene-4-sulfonyloxy)piperidine-1-carboxylic acid tert-butyl ester;1-Boc-4-(tosyloxy)piperidine;(1-BOC-piperidin-4-yl)tosylate;t-Butyl 4-(tosyloxy)piperidine-1-carboxylate;tert-butyl 4-(tosyloxy)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-[[(4-methylphenyl)sulfonyl]oxy]-, 1,1-dimethylethyl ester;1-(tert-Butoxycarbonyl)-4-(p-toluenesulfonyloxy)piperidine
• CAS NO: 118811-07-7
• Molecular Formula: C₁₇H₂₅NO₅S
• Molecular Weight: 355.45
• Mol File: 118811-07-7.mol
• Article Data: 41

Chemical Properties

• Melting Point: 96.0 to 100.0 °C
• Boiling Point: 475.282 °C at 760 mmHg
• Flash Point: 241.242 °C
• Appearance: /
• Density: 1.237 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.553
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: -2.97±0.40(Predicted)
• CAS DataBase Reference: 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(118811-07-7)
• EPA Substance Registry System: 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(118811-07-7)

Safety Data

• Hazardous Substances Data: 118811-07-7(Hazardous Substances Data)

Usage

Description

4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is a piperidine derivative featuring a piperidine ring with a tert-butyl ester group and a toluene-4-sulfonyloxy group. This chemical compound is recognized for its unique structure and reactivity, making it a valuable building block in organic synthesis and pharmaceutical research for the development of bioactive molecules and novel therapeutic agents for various medical conditions.

Uses

Used in Pharmaceutical Research:
4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a building block for the synthesis of bioactive molecules, contributing to the discovery and development of new drugs for a wide range of medical conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 4-(TOLUENE-4-SULFONYLOXY)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is utilized for the creation of complex organic compounds, leveraging its unique reactivity and structural features to facilitate the synthesis of target molecules.

InChI:InChI=1/C17H25NO5S/c1-13-5-7-15(8-6-13)24(20,21)23-14-9-11-18(12-10-14)16(19)22-17(2,3)4/h5-8,14H,9-12H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 98-59-9 p-toluenesulfonyl chloride 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 5382-30-9 1-(1,1-dimethylethyl)-4-piperidinol 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 86953-81-3 tert-butyl 2-hydroxypiperidine-1-carboxylate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 141699-66-3 1-tert-Butyloxycarbonyl-4-(acetylsulfanyl)piperidine 
• 1146362-08-4 tert.butyl 4-[4-(4,5-dihydroxazol-2-yl)-phenoxyl]-piperidine-1-carboxylate 
• 790667-54-8 tert-butyl 4-(3-bromophenoxy)piperidine-1-carboxylate 
• 1251940-27-8 tert-butyl 4-{3-[5-(methylsulfonyl)-2,3-dihydro-1H-indol-1-yl]phenoxy}piperidine-1-carboxylate 
• 1570178-49-2 propan-2-yl 4-{3-[5-(methylsulfonyl)-2,3-dihydro-1H-indol-1-yl]phenoxy}piperidine-1-carboxylate 
• 877399-50-3 4-(4-bromo-1H-pyrazol-1-yl)piperidine-1-carboxylic acid tert-butyl ester 
• 1610034-60-0 (S)-tert-butyl 4-(4-(2-(cyanomethyl)pyrrolidin-1-yl)phenoxy)piperidine-1-carboxylate 
• 1610034-62-2 (S)-2-(1-(4-((1-(2-fluoro-5-methoxyphenyl)piperidin-4-yl)oxy)phenyl)pyrrolidin-2-yl)acetonitrile 
• 1610034-61-1 (S)-2-(1-(4-(piperidin-4-yloxy)phenyl)pyrrolidin-2-yl)acetonitrile 
• 162402-39-3 4-(4-nitrophenoxy)piperidine 
• 1637586-76-5 C₁₇H₁₇FN₂O₅S 
• 1637586-75-4 C₁₉H₁₆F₄N₂O₄ 
• 1637586-78-7 4-((1-((4-fluorophenyl)sulfonyl)piperidin-4-yl)oxy)aniline 
• 1637586-77-6 (4-(4-aminophenoxy)piperidin-1-yl)(3-fluoro-4-(trifluoromethyl)phenyl)methanone 

Relevant articles and documents

Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors

IRAK4 is a key mediator of innate immunity. There is a high interest in identifying novel IRAK4 inhibitors for the treatment of inflammatory autoimmune diseases. We describe here a highly potent and selective IRAK4 inhibitor (HS271) that exhibited superio

Design, synthesis and biological evaluation of 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles as inhibitors of ebola virus infection

Novel 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles were designed and synthesized as Ebola virus inhibitors. The proposed structures of the new prepared benzimidazole-piperidine hybrids were confirmed based on their spectral data and CHN analyses. The target compounds were screened in vitro for their anti-Ebola activity. Among tested molecules, compounds 26a (EC50=0.93 μM, SI = 10) and 25a (EC50=0.64 μM, SI = 20) were as potent as and more selective than Toremifene reference drug (EC50 = 0.38 μM, SI = 7) against cell line. Data suggests that the mechanism by which 25a and 26a block EBOV infection is through the inhibition of viral entry at the level of NPC1. Furthermore, a docking study revealed that several of the NPC1 amino acids that participate in binding to GP are involved in the binding of the most active compounds 25a and 26a. Finally, in silico ADME prediction indicates that 26a is an idealy drug-like candidate. Our results could enable the development of small molecule drug capable of inhibiting Ebola virus, especially at the viral entry step.

8-substituted styryl xanthine derivative and application thereof

The invention discloses an 8-substituted styryl xanthine derivative and application thereof, and particularly relates to a novel 8-substituted styryl xanthine derivative and a pharmaceutical composition containing the compound which can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition, andapplication of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.